HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

temocillin

beta-lactam antibiotic with unusual spectrum of antibacterial activity & exceptional stability to bacterial beta-lactamases; RN given refers to di-Na salt (2S-(2alpha,5alpha,6alpha))-isomer; structure in first source

Also Known As:

BRL 17421; disodium 6beta-(2-carboxy-2-thien-3-ylacetamido)-6alpha-methoxypenicillanate; temocillin, (2S-(2alpha,5alpha,6alpha))-isomer

Networked: 41 relevant articles (10 outcomes, 11 trials/studies) for this Bio-Agent, Comments

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Carryn, Stéphane: 2 articles (11/2008 - 02/2008)
2.	Glupczynski, Y: 2 articles (11/2007 - 11/2001)
3.	Rendall, Jackie: 1 article (11/2008)
4.	Kent, Lisa: 1 article (11/2008)
5.	Jones, Andrew: 1 article (11/2008)
6.	France, Megan: 1 article (11/2008)
7.	Elborn, J Stuart: 1 article (11/2008)
8.	Döring, Gerd: 1 article (11/2008)
9.	Bradley, Judy M: 1 article (11/2008)
10.	Bradbury, Ian: 1 article (11/2008)

Related Diseases

1.	Infection 01/01/1985 - "The therapeutic results observed in 40 patients with various infections (90% fully effective, 5% partially effective) confirm the high efficacy of temocillin in the treatment of gynaecological infections." 11/01/2007 - "Prospective clinical studies are, however, needed to validate the usefulness of temocillin in the treatment of microbiologically documented infections caused by ESBL- and/or AmpC- overproducing nosocomial Enterobacteriaceae pathogens." 04/01/2006 - "Prospective clinical studies are necessary to examine temocillin's potential role in the treatment of non-complicated infections caused by ESBL-producing E. " 01/01/1985 - "In our study, 16 patients with acute infection complicating severe respiratory disease were treated with temocillin 2g or 3g daily for 5 to 10 days. " 01/01/1985 - "In this study 13 patients with a history of chronic respiratory disease were treated with temocillin for severe infection of the lower respiratory tract. " Order ALL the reference details at left...
2.	Abscess 01/01/1985 - "Included in a study of the clinical efficacy of temocillin were 20 hospitalised female patients suffering from infections of the respiratory or urinary tract, septicaemia or an abscess. " 01/01/1985 - "The therapeutic efficacy of the new beta-lactam antibiotic, temocillin, was studied in 30 critically ill patients with peritonitis, abscesses, bronchopneumonia, and serious soft tissue infections. " Order ALL the reference details at left...
3.	Sepsis (Septicemia) 01/01/1985 - "Our results suggest that temocillin may be considered as a potentially useful antibiotic in the treatment of patients with biliary tract sepsis caused by susceptible organisms." 01/01/1985 - "In patients with biliary sepsis, a further reduction in temocillin bile concentrations was observed, and postoperatively, the T-tube bile temocillin concentrations were in the range of 21 to 460 mg/L (mean 130 mg/L). " 01/01/1985 - "Potential role of temocillin in the treatment of biliary sepsis." 05/01/1993 - "The results obtained demonstrate the potential use of temocillin to improve the clinical efficacy of immunotherapeutic monoclonal antibodies in Gram-negative sepsis." 01/01/1985 - "During 1980-1984, 51 patients with enteric fever (typhoid/paratyphoid fever and salmonellosis) biliary tract sepsis, and other Gram-negative infections were treated with temocillin at 3 medical centres in Bangkok, Thailand. " Order ALL the reference details at left...
4.	Renal Insufficiency 04/01/1983 - "Following intravenous administration the total serum clearance of temocillin was reduced in patients with renal insufficiency. " 04/01/1983 - "This relationship has been used to suggest dosage schedules for temocillin in patients with renal insufficiency." Order ALL the reference details at left...
5.	Acute Cholecystitis 01/01/1985 - "The clinical efficacy of temocillin in the 7 patients with acute cholecystitis was judged to be satisfactory. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Monoclonal Antibodies
2.	Ampicillin (Omnipen)
3.	Penicillins (Penicillin)
4.	Imipenem
5.	Cefotaxime (Kendrick)
6.	Drug Combinations
7.	Ciprofloxacin (Cipro)
8.	Chloramphenicol (Chloromycetin)
9.	Cefuroxime (Zinacef)
10.	Anti-Bacterial Agents (Antibiotics)

Related Therapies and Procedures

1.	Intensive Care (Surgical Intensive Care)
2.	Cholecystectomy

blog comments powered by Disqus

TREATMENT OPTIONS
for Infection,
Ranking and Evidence

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 14555 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Evidence References
Sample PDF Report on Psoriasis >>

Price:

$8.50 USD & Delivery via PDF download
updates for 1 year

Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:

Two-clicks from Disease to Drug to Evidence: Drill down to full abstract
Enable Experts: Quickly identify key researchers and their publications
Enable FDA Link Generic: Two-clicks to FDA Products/Patents/Generics
Enable Export: All outcome statements and scores exportable to Excel/TSV for automated meta-analysis
Research Network: Explore drug and disease relationships visually
Enable Mobile Interface: Access from your cellphone, iPhone or PDA

Price:

$45.00 USD access via web interface
1 year subscription

Request Bulk Institution License Details >>